UY26886A1 - Polimorfos de un análogo de epotilona - Google Patents
Polimorfos de un análogo de epotilonaInfo
- Publication number
- UY26886A1 UY26886A1 UY26886A UY26886A UY26886A1 UY 26886 A1 UY26886 A1 UY 26886A1 UY 26886 A UY26886 A UY 26886A UY 26886 A UY26886 A UY 26886A UY 26886 A1 UY26886 A1 UY 26886A1
- Authority
- UY
- Uruguay
- Prior art keywords
- epotilone
- polymorphes
- analog
- methods
- mixtures
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan, de acuerdo con la presente invención, dos polímeros cristalinos, denominados forma A y forma B respectivamente, así como mezclas de los mismos, de un análogo de epotilona representado por la fórmula. También se proporcionan métodos para formar los polimorfos novedosos, métodos terapéuticos que los utilizan y formas de dosificación farmacéutica que los contienen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22559000P | 2000-08-16 | 2000-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26886A1 true UY26886A1 (es) | 2002-03-22 |
Family
ID=22845469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26886A UY26886A1 (es) | 2000-08-16 | 2001-08-15 | Polimorfos de un análogo de epotilona |
Country Status (42)
Country | Link |
---|---|
US (4) | US6689802B2 (es) |
EP (1) | EP1309597B1 (es) |
JP (1) | JP5046467B2 (es) |
KR (1) | KR100810342B1 (es) |
CN (1) | CN1269821C (es) |
AR (1) | AR034259A1 (es) |
AT (1) | ATE366735T1 (es) |
AU (2) | AU2001281082B2 (es) |
BG (1) | BG66132B1 (es) |
BR (1) | BR0113234A (es) |
CA (1) | CA2418109C (es) |
CY (1) | CY1107758T1 (es) |
CZ (1) | CZ305523B6 (es) |
DE (1) | DE60129334T2 (es) |
DK (1) | DK1309597T3 (es) |
EE (1) | EE05273B1 (es) |
ES (1) | ES2288518T3 (es) |
GE (1) | GEP20053495B (es) |
HK (1) | HK1052010A1 (es) |
HR (1) | HRP20030190B1 (es) |
HU (1) | HU229314B1 (es) |
IL (2) | IL153993A0 (es) |
IS (1) | IS2845B (es) |
LT (1) | LT5138B (es) |
LV (1) | LV13032B (es) |
MX (1) | MXPA03001431A (es) |
MY (1) | MY134129A (es) |
NO (1) | NO328500B1 (es) |
NZ (1) | NZ523722A (es) |
PE (1) | PE20020290A1 (es) |
PL (1) | PL205628B1 (es) |
PT (1) | PT1309597E (es) |
RO (1) | RO123296B1 (es) |
RU (1) | RU2272039C2 (es) |
SI (1) | SI21100B (es) |
SK (1) | SK287876B6 (es) |
TW (1) | TWI320040B (es) |
UA (1) | UA75365C2 (es) |
UY (1) | UY26886A1 (es) |
WO (1) | WO2002014323A2 (es) |
YU (1) | YU12103A (es) |
ZA (1) | ZA200300522B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
MXPA03006412A (es) * | 2001-01-25 | 2003-10-15 | Bristol Myers Squibb Co | Metodos para administrar analogos de epotilona para tratamiento de cancer. |
RU2003126171A (ru) * | 2001-01-25 | 2005-02-27 | Бристол-Маерс Сквибб Компани (Us) | Парентеральный состав, содержащий аналоги эпотилона |
MXPA03007394A (es) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Tratamiento de tumores refractarios mediante uso de derivados de epotilona. |
EP1383490B1 (en) * | 2001-03-14 | 2012-04-25 | Bristol-Myers Squibb Company | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases |
DK1485090T3 (da) * | 2002-03-08 | 2008-02-04 | Novartis Ag | Kombinationer omfattende et epothilonderivat og en imidazotetrazinon |
US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
ATE350383T1 (de) * | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
KR20070084325A (ko) | 2004-11-18 | 2007-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법 |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
SI1698630T1 (sl) | 2005-03-03 | 2015-01-30 | Alfa Wassermann S.P.A. | Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih |
CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
US7693596B2 (en) | 2005-12-14 | 2010-04-06 | Dell Products L.P. | System and method for configuring information handling system integrated circuits |
US20080286325A1 (en) * | 2006-01-05 | 2008-11-20 | Med Institute, Inc. | Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent |
US7919108B2 (en) * | 2006-03-10 | 2011-04-05 | Cook Incorporated | Taxane coatings for implantable medical devices |
US7875284B2 (en) * | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
WO2007117439A2 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
US8163792B2 (en) | 2006-05-16 | 2012-04-24 | Pharmascience Inc. | IAP BIR domain binding compounds |
CL2007002362A1 (es) | 2006-08-16 | 2008-08-08 | Novartis Ag | Forma de cristal de la epotilona b; composicion farmaceutica que la comprende; y uso para el tratamiento de una enfermedad proliferativa, tal como un tumor. |
US8463852B2 (en) * | 2006-10-06 | 2013-06-11 | Oracle International Corporation | Groupware portlets for integrating a portal with groupware systems |
WO2008103916A2 (en) * | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia Univeristy In The City Of New York | Compositions and methods for treating cancer or a neurotrophic disorder |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
SG10201501095WA (en) | 2010-02-12 | 2015-04-29 | Pharmascience Inc | Iap bir domain binding compounds |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
KR20130086534A (ko) * | 2010-06-01 | 2013-08-02 | 플러스 케미칼스, 에스.에이. | 익사베필론의 고체 형태 |
CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
CN103183681B (zh) * | 2013-03-06 | 2016-01-13 | 浙江海正药业股份有限公司 | 伊沙匹隆的新晶型及其制备方法 |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
CA2914189C (en) | 2013-06-21 | 2023-03-14 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
AU2021212305A1 (en) | 2020-01-31 | 2022-08-11 | Allarity Therapeutics Europe ApS | Methods for predicting ixabepilone responsiveness in cancer patients |
CN112409366A (zh) * | 2020-11-30 | 2021-02-26 | 湖北宏中药业股份有限公司 | 一种伊沙匹隆二聚体的高收率制备方法 |
CN112375085A (zh) * | 2020-11-30 | 2021-02-19 | 湖北宏中药业股份有限公司 | 一种伊沙匹隆反应液的高收率高纯度处理方法 |
CN112457320A (zh) * | 2020-11-30 | 2021-03-09 | 湖北宏中药业股份有限公司 | 一种提高伊沙匹隆合成反应速率的方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1000809A (en) * | 1960-11-02 | 1965-08-11 | James Oakes & Company Riddings | Pipe manufacture |
DE2308418B2 (de) * | 1972-06-21 | 1976-04-08 | Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) | Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff |
JPS5240337B2 (es) * | 1973-01-29 | 1977-10-12 | ||
SE386365B (sv) * | 1973-07-25 | 1976-08-09 | L Brendling | Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier |
JPS6398413A (ja) * | 1986-10-15 | 1988-04-28 | Smc Corp | 二重管およびその連続製造法 |
DE3927569A1 (de) * | 1989-08-21 | 1991-02-28 | Fritz Egger Gmbh | Elektroabscheider zum abscheiden von schwebstoffen aus gasen |
DE3939714A1 (de) * | 1989-12-01 | 1991-06-06 | Baedje K H Meteor Gummiwerke | Schlauch |
AU6431790A (en) * | 1990-01-05 | 1991-08-05 | Orscheln Co. | Flexible synthetic plastic conduit |
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
DE4206096A1 (de) * | 1992-02-27 | 1993-09-02 | Wolf Woco & Co Franz J | Koaxialrohr |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
PT1186606E (pt) | 1995-11-17 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | Derivados do epotilone sua preparacao e utilizacao |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
DK1367057T3 (da) * | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
CN1544436A (zh) | 1997-02-25 | 2004-11-10 | ���\���о�����˾��GBF�� | 3,7-保护的环氧噻嗪酮-n-氧化物及其制备方法 |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
US6348551B1 (en) | 1997-04-18 | 2002-02-19 | Studiengesellschaft Kohle Mbh | Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
DK1001951T3 (da) | 1997-07-16 | 2002-12-23 | Schering Ag | Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse |
US7407975B2 (en) | 1997-08-09 | 2008-08-05 | Bayer Schering Pharma Ag | Epothilone derivatives, method for producing same and their pharmaceutical use |
DE19747580A1 (de) | 1997-10-28 | 1999-04-29 | Siemens Ag | Rangierfeld mit Anschlußleiste |
US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
NZ506389A (en) | 1998-02-05 | 2003-07-25 | Novartis Ag | Pharmaceutical compositions containing epothilone which can be optionally lyophilised |
US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
DE19807505A1 (de) | 1998-02-21 | 1999-08-26 | Roland Man Druckmasch | Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
CA2322157C (en) | 1998-02-25 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
AU5325699A (en) * | 1998-08-12 | 2000-03-06 | Proteus Inc. | Ribbed core dual wall structure |
CA2352505C (en) | 1998-12-22 | 2009-04-07 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
AR023792A1 (es) | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
US6605559B1 (en) * | 1999-09-29 | 2003-08-12 | Daihatsu Motor Co., Ltd. | Dimethyl ether reforming catalyst |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
EP1353668B1 (en) | 2001-01-25 | 2008-03-19 | Bristol-Myers Squibb Company | Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer |
RU2003126171A (ru) * | 2001-01-25 | 2005-02-27 | Бристол-Маерс Сквибб Компани (Us) | Парентеральный состав, содержащий аналоги эпотилона |
US9317043B2 (en) | 2013-12-19 | 2016-04-19 | Google Inc. | Path based power generation control for an aerial vehicle |
-
2001
- 2001-01-08 UA UA2003032259A patent/UA75365C2/uk unknown
- 2001-07-26 MY MYPI20013545 patent/MY134129A/en unknown
- 2001-08-01 YU YU12103A patent/YU12103A/sh unknown
- 2001-08-01 GE GE5091A patent/GEP20053495B/en unknown
- 2001-08-01 DE DE60129334T patent/DE60129334T2/de not_active Expired - Lifetime
- 2001-08-01 EP EP01959536A patent/EP1309597B1/en not_active Expired - Lifetime
- 2001-08-01 JP JP2002519462A patent/JP5046467B2/ja not_active Expired - Fee Related
- 2001-08-01 AU AU2001281082A patent/AU2001281082B2/en not_active Ceased
- 2001-08-01 RO ROA200300114A patent/RO123296B1/ro unknown
- 2001-08-01 SI SI200120055A patent/SI21100B/sl not_active IP Right Cessation
- 2001-08-01 BR BR0113234-2A patent/BR0113234A/pt active Search and Examination
- 2001-08-01 KR KR1020037002256A patent/KR100810342B1/ko not_active IP Right Cessation
- 2001-08-01 EE EEP200300063A patent/EE05273B1/xx not_active IP Right Cessation
- 2001-08-01 PL PL365610A patent/PL205628B1/pl unknown
- 2001-08-01 AU AU8108201A patent/AU8108201A/xx active Pending
- 2001-08-01 NZ NZ523722A patent/NZ523722A/en not_active IP Right Cessation
- 2001-08-01 AT AT01959536T patent/ATE366735T1/de active
- 2001-08-01 PT PT01959536T patent/PT1309597E/pt unknown
- 2001-08-01 WO PCT/US2001/024540 patent/WO2002014323A2/en active IP Right Grant
- 2001-08-01 SK SK134-2003A patent/SK287876B6/sk not_active IP Right Cessation
- 2001-08-01 CN CNB018170641A patent/CN1269821C/zh not_active Expired - Lifetime
- 2001-08-01 CZ CZ2003-418A patent/CZ305523B6/cs not_active IP Right Cessation
- 2001-08-01 DK DK01959536T patent/DK1309597T3/da active
- 2001-08-01 RU RU2003106431/04A patent/RU2272039C2/ru active
- 2001-08-01 IL IL15399301A patent/IL153993A0/xx unknown
- 2001-08-01 HU HU0300826A patent/HU229314B1/hu not_active IP Right Cessation
- 2001-08-01 ES ES01959536T patent/ES2288518T3/es not_active Expired - Lifetime
- 2001-08-01 MX MXPA03001431A patent/MXPA03001431A/es active IP Right Grant
- 2001-08-01 CA CA2418109A patent/CA2418109C/en not_active Expired - Lifetime
- 2001-08-09 US US09/925,112 patent/US6689802B2/en not_active Ceased
- 2001-08-10 TW TW090119585A patent/TWI320040B/zh not_active IP Right Cessation
- 2001-08-15 UY UY26886A patent/UY26886A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103901A patent/AR034259A1/es not_active Application Discontinuation
- 2001-08-16 PE PE2001000818A patent/PE20020290A1/es not_active Application Discontinuation
-
2003
- 2003-01-16 IL IL153993A patent/IL153993A/en not_active IP Right Cessation
- 2003-01-16 BG BG107467A patent/BG66132B1/bg unknown
- 2003-01-20 ZA ZA200300522A patent/ZA200300522B/en unknown
- 2003-02-11 IS IS6714A patent/IS2845B/is unknown
- 2003-02-14 NO NO20030707A patent/NO328500B1/no not_active IP Right Cessation
- 2003-02-25 LT LT2003017A patent/LT5138B/lt not_active IP Right Cessation
- 2003-03-07 LV LVP-03-28A patent/LV13032B/en unknown
- 2003-03-14 HR HR20030190A patent/HRP20030190B1/xx not_active IP Right Cessation
- 2003-06-17 HK HK03104338A patent/HK1052010A1/xx not_active IP Right Cessation
-
2004
- 2004-02-06 US US10/773,819 patent/US6982276B2/en not_active Expired - Lifetime
-
2005
- 2005-03-09 US US11/076,589 patent/USRE39251E1/en not_active Expired - Lifetime
- 2005-11-10 US US11/271,456 patent/US7153879B2/en not_active Expired - Lifetime
-
2007
- 2007-10-11 CY CY20071101304T patent/CY1107758T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26886A1 (es) | Polimorfos de un análogo de epotilona | |
CO6362017A2 (es) | Peptidos antivirales terapeuticos | |
CR6726A (es) | Compuestos azapoliciclicos condensados con arilo | |
UY27427A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos | |
UY26958A1 (es) | Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación | |
ATE478685T1 (de) | Prodrugs mit neuen biospaltbaren verbindern | |
AR077415A2 (es) | Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos | |
UY27226A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
UY28859A1 (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento | |
SE0302811D0 (sv) | Novel compounds | |
UY27222A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
AR048741A1 (es) | Derivados de omega-carboxiaril difenil urea sustituida | |
AR048912A1 (es) | Inmunoglobulinas anti-nogo | |
CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
ATE441630T1 (de) | Substituierte cyclopenten-verbindungen | |
AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
AR047922A1 (es) | Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos | |
BRPI0519710A2 (pt) | aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio | |
CY1108793T1 (el) | Καμπτοθεκινες με τροποποιημενο λακτονικο δακτυλιο | |
ECSP066964A (es) | Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos | |
BRPI0415203A (pt) | pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios | |
ECSP034531A (es) | Derivados sustituidos de c-ciclohexilmetilamina | |
GT200800066A (es) | Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento. | |
GT200500381A (es) | Derivado de quinolina, su uso, preparacion y medicamento que lo contiene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20141001 |